Trial Profile
Phase I/Ib Trial of Single Agent PBF-509 and in Combination With PDR001 for Patients With Advanced NSCLC
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Spartalizumab (Primary) ; Taminadenant (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms AdenONCO
- Sponsors Palobiofarma
- 07 Mar 2022 Results published in the Clinical Cancer Research
- 03 Jan 2022 Status changed from active, no longer recruiting to completed.
- 28 Jun 2020 Status changed from recruiting to active, no longer recruiting.